ramucirumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4917 947687-13-0

Description:

MoleculeDescription

Synonyms:

  • ramucirumab
  • cyramza
  • IMC-1121B
Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 26, 2015 PMDA Eli Lilly Japan K.K.
Dec. 19, 2014 EMA Eli Lilly Nederland B.V.
April 21, 2014 FDA ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 296.38 41.12 105 1762 82016 63405139
Ascites 119.90 41.12 45 1822 40683 63446472
Nephrotic syndrome 66.82 41.12 18 1849 5558 63481597
Disease progression 60.18 41.12 40 1827 122718 63364437
Proteinuria 59.33 41.12 22 1845 19123 63468032
Neutropenia 55.98 41.12 44 1823 174961 63312194
Death 51.68 41.12 59 1808 374322 63112833
Gastrointestinal perforation 45.28 41.12 12 1855 3479 63483676
Neutrophil count decreased 41.92 41.12 24 1843 56382 63430773

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 420.25 29.79 196 3407 87850 34865478
Febrile neutropenia 101.22 29.79 95 3508 136754 34816574
Interstitial lung disease 89.63 29.79 65 3538 65217 34888111
Neutrophil count decreased 63.59 29.79 48 3555 51056 34902272
Gastric perforation 62.87 29.79 19 3584 2501 34950827
Disease progression 61.20 29.79 65 3538 108012 34845316
Neutropenia 59.90 29.79 77 3526 156701 34796627
Decreased appetite 56.29 29.79 77 3526 166315 34787013
Tumour haemorrhage 55.73 29.79 18 3585 2944 34950384
Proteinuria 51.74 29.79 29 3574 18613 34934715
Neuropathy peripheral 46.94 29.79 50 3553 83213 34870115
Metastases to liver 39.94 29.79 22 3581 13641 34939687
Peritonitis 36.25 29.79 22 3581 16343 34936985
Death 33.38 29.79 103 3500 397946 34555382
Ascites 31.72 29.79 31 3572 46540 34906788

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 580.86 30.88 245 4989 135745 79603409
Ascites 136.88 30.88 76 5158 75486 79663668
Disease progression 126.17 30.88 101 5133 184261 79554893
Febrile neutropenia 126.02 30.88 111 5123 230888 79508266
Interstitial lung disease 120.85 30.88 81 5153 112519 79626635
Neutrophil count decreased 109.06 30.88 71 5163 93888 79645266
Neutropenia 107.10 30.88 112 5122 287598 79451556
Proteinuria 106.92 30.88 49 5185 32453 79706701
Tumour haemorrhage 83.85 30.88 24 5210 4120 79735034
Neuropathy peripheral 79.09 30.88 69 5165 141236 79597918
Decreased appetite 78.44 30.88 104 5130 342314 79396840
Gastric perforation 75.53 30.88 22 5212 4015 79735139
Nephrotic syndrome 67.57 30.88 26 5208 11148 79728006
Peritonitis 67.10 30.88 34 5200 28002 79711152
Gastrointestinal perforation 54.66 30.88 19 5215 6118 79733036
Pyogenic granuloma 52.68 30.88 11 5223 504 79738650
Therapy partial responder 47.25 30.88 23 5211 17374 79721780
Glomerular vascular disorder 37.11 30.88 7 5227 189 79738965
Death 36.50 30.88 100 5134 566414 79172740
Haematotoxicity 34.74 30.88 18 5216 15501 79723653
Pneumonitis 34.55 30.88 30 5204 60830 79678324
Epistaxis 32.00 30.88 38 5196 111477 79627677
Tumour perforation 31.78 30.88 7 5227 414 79738740

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FG02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
FDA MoA N0000020032 VEGFR2 Inhibitors
FDA EPC N0000191009 Vascular Endothelial Growth Factor Receptor 2 Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Non-small cell lung cancer indication 254637007 DOID:3908
Malignant tumor of stomach indication 363349007 DOID:10534
Adenocarcinoma of stomach indication 408647009 DOID:3717
Malignant neoplasm of colon and/or rectum indication 781382000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vascular endothelial growth factor receptor 2 Kinase ANTIBODY BINDING Kd 10.30 IUPHAR DRUG LABEL

External reference:

IDSource
D99YVK4L0X UNII
D09371 KEGG_DRUG
4033300 VUID
N0000190752 NUI
4033300 VANDF
C2742502 UMLSCUI
CHEMBL1743062 ChEMBL_ID
DB05578 DRUGBANK_ID
9098 INN_ID
C543333 MESH_SUPPLEMENTAL_RECORD_UI
7390 IUPHAR_LIGAND_ID
1535922 RXNORM
219168 MMSL
30265 MMSL
d08252 MMSL
015502 NDDF
704259004 SNOMEDCT_US
704260009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CYRAMZA HUMAN PRESCRIPTION DRUG LABEL 1 0002-7669 SOLUTION 10 mg INTRAVENOUS BLA 28 sections
CYRAMZA HUMAN PRESCRIPTION DRUG LABEL 1 0002-7669 SOLUTION 10 mg INTRAVENOUS BLA 28 sections
CYRAMZA HUMAN PRESCRIPTION DRUG LABEL 1 0002-7669 SOLUTION 10 mg INTRAVENOUS BLA 28 sections
CYRAMZA HUMAN PRESCRIPTION DRUG LABEL 1 0002-7678 SOLUTION 10 mg INTRAVENOUS BLA 28 sections
CYRAMZA HUMAN PRESCRIPTION DRUG LABEL 1 0002-7678 SOLUTION 10 mg INTRAVENOUS BLA 28 sections
CYRAMZA HUMAN PRESCRIPTION DRUG LABEL 1 0002-7678 SOLUTION 10 mg INTRAVENOUS BLA 28 sections